As previously disclosed, on December 2, 2019, Audentes Therapeutics, Inc., Astellas Pharma Inc. and Asilomar Acquisition Corp. entered into an Agreement and Plan of Merger (the “Merger Agreement”). In connection with the Merger, effective at the Effective Time, (i) each of Matthew Patterson, Mark Goldberg, M.D., Louis Lange, M.D., Ph.D., Jennifer Jarrett, Scott Morrison, Thomas Schuetz, M.D., Ph.D. and Julie Smith resigned from his or her respective position as a member of the Company's Board of Directors, and each committee thereof, and (ii) Matthew Patterson ceased to be an executive officer of the Company.

These resignations were not a result of any disagreement between the Company and the directors on any matter relating to the Company's operations, policies or practices. At the Effective Time, (i) each of Natalie Holles, Percival Barretto-Ko, Masaaki Hirano and Toru Yoshimitsu became directors of the Company, (ii) Natalie Holles became the President and Chief Executive Officer of the Company and (iii) Thomas Soloway became the Treasurer of the Company. In addition, Thomas Soloway will remain in his position as Senior Vice President and Chief Financial Officer of the Company.